Article
EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the "Rebiopsy on Osi" study).
The oncologist - 6 Aug 2026
Gariazzo Eleonora, Colamartini Francesca, Cantale Ornella, Mogavero Andrea, Vitale Antonio, Romano Luca, Peroni Marianna, Rijavec Erika, Banini Marco, Mazzoni Sofia, Montrone Mirko, Pasello Giulia, Veccia Antonello, Ogliari Francesca Rita, Leo Silvana, Cortinovis Diego, Delmonte Angelo, Belluomini Lorenzo, La Cava Giulia, Meoni Giulia, Sini Claudio, Delcuratolo Marco Donatello, Bettini Anna, Pagano Maria, Genova Carlo, Russo Alessandro, Pelizzari Giacomo, Tondulli Luca, Sergi Concetta, Roca Elisa, Bennati Chiara, Grisanti Salvatore, Stanzione Brigida, Mariotti Sabrina, Vavalà Tiziana, Soto Parra Hector, Ortega Cinzia, Pignataro Daniele, Lacidogna Gaetano, Pino Maria Simona, Chiari Rita, Calabrò Luana, Pozzessere Daniele, Masini Silvia, Gelibter Alain, Scotti Vieri, Grossi Francesco, Tiseo Marcello, Bria Emilio, Metro Giulio
Abstract excerpt
BACKGROUND: Although rebiopsy at progression on osimertinib is recommended for patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC), its real-world impact on clinical outcomes remains unclear. Rebiopsy on Osi is a multicenter, retrospective study assessing rebiopsy patterns, resistance mechanisms, and their impact on second-line treatment choices and outcomes in routine clinical practice....
Read the complete abstract on PubMed